Iheezo Cuts Eye-Injection Discomfort 58% in Head-to-Head Study
HROW sits 46% above its 52-week low of $28.54 on light trading volume (0.3× avg).
Summary
Harrow's IHEEZO gel reduced patient discomfort by 58% versus standard proparacaine in a randomized contralateral-eye study of bilateral intravitreal injections. The benefit was statistically significant at all four time points, with the largest absolute difference immediately post-injection. William Blair sees the data as supportive of the ongoing Phase IV QUELL study readout expected later this year and maintains an Outperform rating. This adds clinical differentiation to IHEEZO and could drive adoption among retina specialists, though the stock traded down 1.33% on the day.
At the time of this announcement, HROW was trading at $41.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $28.54 to $54.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.